Chemoproteomics enables identification of coatomer subunit zeta-1 targeted by a small molecule for enterovirus A71 inhibition

Abstract

Human enterovirus A71 (EV-A71) is a significant etiological agent responsible for epidemics of hand, foot, and mouth disease (HFMD) in Asia-Pacific regions. There are presently no licensed antivirals against EV-A71, and the druggable target for EV-A71 remains very limited. The phenotypic hit 10,10′-bis(trifluoromethyl) marinopyrrole A derivative, herein termed MPA-CF₃, is a novel potent small-molecule inhibitor against EV-A71, but its pharmacological target(s) and antiviral mechanisms are not defined. Here, quantitative chemoproteomics deciphered the antiviral target of MAP-CF₃ as host factor coatomer subunit zeta-1 (COPZ1). Mechanistically, MPA-CF₃ disrupts the interaction of COPZ1 with the EV-A71 nonstructural protein 2C by destabilizing COPZ1 upon binding. The destruction of this interaction blocks the coatomer-mediated transport of 2C to endoplasmic reticulum, and ultimately inhibits EV-A71 replication. Taken together, our study disclosed that MPA-CF₃ can be a structurally novel host-targeting anti-EV-A71 agent, providing a structural basis for developing the COPZ1-targeting broad-spectrum antivirals against enteroviruses. The mechanistic elucidation of MPA-CF₃ against EV-A71 may offer an alternative COPZ1-involved therapeutic pathway for enterovirus infection.

Keywords

chemoproteomics / coatomer subunit zeta-1 / enterovirus A71 / marinopyrrole A derivate

References

1	D Nasri, L Bouslama, S Pillet, et al. Basic rationale, current methods and future directions for molecular typing of human enterovirus. Expert Rev Mol Diagn. 2007;7(4):419-434.
2	W Xing, Q Liao, C Viboud, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308-318.
3	M Lee, T Lin, P Chiang, et al. An investigation of epidemic enterovirus 71 infection in Taiwan, 2008. Pediatr Infect Dis J. 2010;29(11):1030-1034.
4	S Liu, H Pan, P Liu, et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol. 2015;25(2):115-128.
5	MH Ooi, SC Wong, Y Podin, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44(5):646-656.
6	SM Wang, HY Lei, KJ Huang, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003;188(4):564-570.
7	F Zhu, W Xu, J Xia, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818-828.
8	R Li, L Liu, Z Mo, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829-837.
9	FC Zhu, FY Meng, JX Li, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024-2032.
10	F Vincent, A Nueda, J Lee, et al. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022;21(12):899-914.
11	Y Xiao, J Yang, L Zou, et al. Synthesis of 10,10′-bis(trifluoromethyl) marinopyrrole A derivatives and evaluation of their antiviral activities in vitro. Eur J Med Chem. 2022;238:114436.
12	S Mohammed, AJR Heck, PJ Boersema, et al. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc. 2009;4(4):484-494.
13	J Hsu, S Huang, N Chow, et al. Stable-isotope dimethyl labeling for quantitative proteomics. Anal Chem. 2003;75(24):6843-6852.
14	X Li, M Wang, A Cheng, et al. Enterovirus replication organelles and inhibitors of their formation. Front Microbiol. 2020:11.
15	M Sachse, DCI Fernández, R Tenorio, et al. The viral replication organelles within cells studied by electron microscopy. Adv Virus Res. 2019;105:1-33.
16	NY Hsu, O Ilnytska, G Belov, et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010;141(5):799-811.
17	N Gomez-Navarro, EA Miller. COP-coated vesicles. Curr Biol. 2016;26(2):R54-R57.
18	J Wang, Z Wu, Q Jin. COPI is required for enterovirus 71 replication. PLoS One. 2012;7(5):e38035.
19	S Lunev, MFW Semmelink, JL Xian, et al. Crystal structure of truncated human coatomer protein complex subunit ζ1 (Copζ1). Acta Crystallogr F Struct Biol Commun. 2017;73(1):1-8.
20	E Kazlauskas, V Petrauskas, V Paketuryt?, et al. Standard operating procedure for fluorescent thermal shift assay (FTSA) for determination of protein-ligand binding and protein stability. Eur Biophys J. 2021;50(3-4):373-379.
21	RJ Taylor, G Tagiltsev, J Briggs. The structure of COPI vesicles and regulation of vesicle turnover. Febs Lett. 2023;597(6):819-835.
22	O Kuge, S Hara-Kuge, L Orci, et al. zeta-COP, a subunit of coatomer, is required for COP-coated vesicle assembly. J Cell Biol. 1993;123(6 Pt 2):1727-1734.
23	S Wang, K Wang, K Zhao, et al. The structure, function, and mechanisms of action of enterovirus non-structural protein 2C. Front Microbiol. 2020:11.
24	WF Tang, SY Yang, BW Wu, et al. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. J Biol Chem. 2007;282(8):5888-5898.
25	J Hong, F Liu, H Qi, et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013–2019: a population-based study. Lancet Reg Health West Pac. 2022;20:100370.
26	SP Chen, YC Huang, WC Li, et al. Comparison of clinical features between coxsackievirus A2 and enterovirus 71 during the enterovirus outbreak in Taiwan, 2008: a children's hospital experience. J Microbiol Immunol Infect. 2010;43(2):99-104.
27	KY Lee. Enterovirus 71 infection and neurological complications. Korean J Pediatr. 2016;59(10):395.
28	J Wang, Y Hu, M Zheng. Enterovirus A71 antivirals: past, present, and future. Acta Pharm Sin B. 2022;12(4):1542-1566.
29	M Zhang, Y Wang, W He, et al. Design, synthesis, and evaluation of novel enterovirus 71 inhibitors as therapeutic drug leads for the treatment of human hand, foot, and mouth disease. J Med Chem. 2020;63(3):1233-1244.
30	L De Colibus, X Wang, JAB Spyrou, et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol. 2014;21(3):282-288.
31	P Li, J Yu, F Hao, et al. Discovery of potent EV71 capsid inhibitors for treatment of HFMD. Acs Med Chem Lett. 2017;8(8):841-846.
32	Q Tang, Z Xu, F Zhang, et al. Identification of a novel binding inhibitor that blocks the interaction between hSCARB2 and VP1 of enterovirus 71. Cell Insight. 2022;1(2):100016.
33	G Ma, Y Ye, D Zhang, et al. Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening. Eur J Med Chem. 2016;124:981-991.
34	Y Hu, R Musharrafieh, M Zheng, et al. Enterovirus D68 antivirals: past, present, and future. Acs Infect Dis. 2020;6(7):1572-1586.
35	Q Tang, Z Xu, M Jin, et al. Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: in vitro, in vivo, and combination therapy study. Eur J Med Chem. 2020;202:112310.
36	E Domingo, JJ Holland. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151-178.
37	R Sanjuán, P Domingo-Calap. Mechanisms of viral mutation. Cell Mol Life Sci. 2016;73(23):4433-4448.
38	HM van der Schaar, P Leyssen, HJ Thibaut, et al. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ. Antimicrob Agents Chemother. 2013;57(10):4971-4981.
39	JR Strating, L van der Linden, L Albulescu, et al. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep. 2015;10(4):600-615.
40	R Duden. ER-to-Golgi transport: cOP I and COP II function (Review). Mol Membr Biol. 2003;20(3):197-207.
41	MC Anania, E Cetti, D Lecis, et al. Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. Cancer Lett. 2017;410:201-211.
42	Y Zhang, Y Kong, Y Ma, et al. Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines. Oncogene. 2021;40(8):1425-1439.
43	Y Hong, Z Xia, Y Sun, et al. A comprehensive pan-cancer analysis of the regulation and prognostic effect of coat complex subunit zeta 1. Genes-Basel. 2023;14(4):889.
44	MJ Niphakis, BF Cravatt. Enzyme inhibitor discovery by activity-based protein profiling. Annu Rev Biochem. 2014;83:341-377.
45	CY Chang, JR Li, YC Ou, et al. Enterovirus 71 infection caused neuronal cell death and cytokine expression in cultured rat neural cells. Iubmb Life. 2015;67(10):789-800.
46	Y Wang, K Dan, X Xue, et al. Curcumin assists anti-EV71 activity of IFN-α by inhibiting IFNAR1 reduction in SH-SY5Y cells. Gut Pathog. 2022;14(1).
47	D Chen, C Chen, J Tan, et al. ERK inhibition aids IFN-β promoter activation during EV71 infection by blocking CRYAB degradation in SH-SY5Y cells. Pathog Dis. 2023:81.
48	KX Wu, JJ Chu. Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor. Antivir Res. 2017;143:122-133.
49	T Hao, Y Li, S Fan, et al. Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent. Eur J Med Chem. 2019;175:172-186.
50	Z Li, P Hao, L Li, et al. Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling. Angew Chem Int Ed Engl. 2013;52(33):8551-8556.
51	YG Li, JX Wang, GN Zhang, et al. Design, synthesis, and biological activity evaluation of a series of pleuromutilin derivatives with novel C14 side chains. Bioorg Med Chem Lett. 2020;30(7):126969.
52	F Yang, J Gao, J Che, et al. A dimethyl-labeling-based strategy for site-specifically quantitative chemical proteomics. Anal Chem. 2018;90(15):9576-9582.
53	Z Li, L Xu, D He, et al. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS One. 2014;9(10):e109391.
54	M Shtutman, M Baig, E Levina, et al. Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit ζ 2 renders tumor cells dependent on its paralogous gene COPZ1. Proc Natl Acad Sci USA. 2011;108(30):12449-12454.
55	Y Li, M Liu, Y Yan, et al. Molnupiravir and its active form, EIDD-1931, show potent antiviral activity against enterovirus infections in vitro and in vivo. Viruses. 2022;14(6):1142.
56	LJ Reed, H Muench. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493-497.[CrossRef]